Roche exits epigenetic drug deal
After 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Ablynx adds Sanofi to its list of pharma partners
Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Shire licensed bispecific antibody from Novimmune
Swiss biopharmaceutical company Novimmune grants pharma company Shire a worldwide license to develop and commercialise a pre-clinical bispecific antibody candidate for haemophilia A.
One cell, many discoveries
Be ready for the next generation of cell analysis and isolation with BD FACSMelody.
UK invests £86m in healthcare SMEs
The UK government has set up a new fund to support medical innovation. Breakthrough innovations that have the potential to benefit the NHS will also undergo accelerated access review aimed at speeding up access to novel medicines.
German PEI limits use of daclizumab
Following a safety warning of the EMA on deaths related to Biogen’s multiple scleroisis (MS) drug Zinbryta (daclizumab), German regulatory authority has issued a red hand letter.
Microbiome shows COPD subtypes
German researchers have found that the lung microbiome is indicative for different subtypes of chronic obstructive pulmonary disease (COPD).
Psoriasis: FDA approves guselkumab
The Food and Drug Administration has granted US market approval to Janssen Biotech/MorphoSys’ IL23 blocker guselkumab (Temfya) as therapy for moderate to severe psoriasis.
ODAC greenlights Novartis’ CAR-T cell therapy CTL019
Swiss Novartis is about to receive the very first market approval (BLA) for a CAR-T cell cancer therapy globally. The FDA’s Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019 (tisagenlecleucel) for the treatment of the orphan B-cell blood cancer ALL.
Enterome and Nestlé form JV
French gut microbiome analysis specialist Enterome Bioscience SA and therapeutic nutrition company Nestlé Health Science have formed a 50:50 joint venture aimed at developing microbiome-based diagnostics for certain common diseases.